Galectin Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference
August 28, 2018 08:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H....
Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
June 27, 2018 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., June 27, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
Galectin Therapeutics Inc. Announces New CEO
June 12, 2018 08:32 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., June 12, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H....
Galectin Therapeutics Inc. Announces Richard E. Uihlein Elected Chairman of the Board
June 04, 2018 09:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., June 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the directors...
OmniSeq and LabCorp Launch OmniSeq Advance℠ Assay
June 01, 2018 16:11 ET
|
OmniSeq
CHICAGO, June 01, 2018 (GLOBE NEWSWIRE) -- ASCO – OmniSeq®, a CAP-accredited, molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE:LH), a leading...
Rhizen Pharmaceuticals S.A. Announces Presentations on Tenalisib (RP6530) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 29, 2018 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, May 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., a clinical-stage biotechnology company developing Tenalisib (RP6530), a highly selective and orally...
Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting
May 14, 2018 09:05 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it is proceeding with...
Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update
May 11, 2018 16:10 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 11, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
April 18, 2018 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 18, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber,...
Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
April 04, 2018 09:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today the presentation of a...